Sana Biotechnology, Inc. ((SANA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Sana Biotechnology, Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM).’ The study aims to assess the safety, tolerability, and preliminary clinical response of SC291 in treating severe autoimmune diseases, highlighting its potential significance in addressing conditions like Lupus and Vasculitis.
Intervention/Treatment: The intervention being tested is SC291, a biological allogeneic CAR T cell therapy. It is designed to target CD19 and is intended to treat severe autoimmune diseases by modulating immune responses.
Study Design: This interventional study employs a non-randomized, sequential intervention model with no masking. The primary purpose is treatment, focusing on evaluating the effects of SC291 in a controlled setting.
Study Timeline: The study began on February 12, 2024, with the latest update submitted on April 10, 2025. These dates are crucial as they indicate the study’s progression and ongoing recruitment status.
Market Implications: The update on this study could positively influence Sana Biotechnology’s stock performance, as successful outcomes may boost investor confidence. The competitive landscape in autoimmune disease treatment is evolving, and advancements in CAR T cell therapy could position Sana favorably against competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.